Valvular heart disease in a patient with Parkinson's disease treated with a low daily dose and a low cumulative dose of pergolide [7]

Movement Disorders

Volumn 21, Issue 4, 2006, Pages 586-587

  Chung, Eun Joo ^a   Yoon, Won Tae ^a   Kim, Ji Youn ^a   Lee, Won Yong ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

PERGOLIDE;

ADULT; ANAMNESIS; ANGINA PECTORIS; AORTA VALVE REGURGITATION; CASE REPORT; CHORDA TENDINEA RUPTURE; CLINICAL FEATURE; DOSE RESPONSE; DYSPNEA; ECHOCARDIOGRAPHY; HEART FAILURE; HEART FUNCTION TEST; HEART VALVE SURGERY; HISTOPATHOLOGY; HOLTER MONITORING; HUMAN; LETTER; LOW DRUG DOSE; MALE; MITRAL VALVE DISEASE; MITRAL VALVE REGURGITATION; MITRAL VALVE REPLACEMENT; PARKINSON DISEASE; PLEURA EFFUSION; PRIORITY JOURNAL; TREATMENT DURATION; TRICUSPID VALVE REGURGITATION; VALVULAR HEART DISEASE;

ANTIPARKINSON AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHOCARDIOGRAPHY; HEART VALVE DISEASES; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PERGOLIDE;

EID: 33646262311     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.20813     Document Type: Letter

References (9)

1. Pritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM, Espinosa RE. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2002;77:1280-1286.
2. Flowers CM, Racoosin JA, Lu SL, Beitz JG. The U.S. Food and Drug Administration's registry of patients with pergolide-associated valvular heart disease. Mayo Clin Proc 2003;78:730-731.
3. Van Camp G, Flamez A, Cosyns B, Goldstein J, Perdaens C, Schoors D. Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide. Neurology 2003;61:859-861.
4. Baseman DG, O'Suilleabhain PE, Reimold SC, Laskar SR, Baseman JG, Dewey RB. Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology 2004;63:301-304.
5. Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004;363:1179-1183.
6. Horvath J, Fross RD, Fisman GK, et al. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 2004;19:656-662.
7. Waller EA, Kaplan J, Heckman MG. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2005;80:1016-1020.
8. Rahimtoola SH. Drug-related valvular heart disease: here we go again - will we do better this time? Mayo Clin Proc 2002;77:1275-1277.
9. Lanier WL. Additional insights into pergolide-associated valvular heart disease. Mayo Clin Proc 2003;78:684-686.